Ligand validation:3C09

NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose

NAG is a Ligand Of Interest in 3C09 designated by the RCSB

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
3C09_NAG_D_3281	63%	43%	0.161	0.969	0.68	1.54	-	3	4	0	93%	0.9333
3C09_NAG_D_3282	55%	42%	0.15	0.932	0.68	1.61	-	2	1	0	93%	0.9333
3C09_NAG_A_3281	49%	34%	0.197	0.958	0.85	1.82	1	3	6	0	93%	0.9333
3C09_NAG_A_3282	41%	39%	0.199	0.927	0.74	1.67	-	3	3	0	93%	0.9333
3C09_NAG_A_4201	31%	45%	0.211	0.892	0.63	1.52	-	3	0	0	93%	0.9333
3C09_NAG_A_3891	18%	55%	0.197	0.798	0.6	1.12	-	2	1	0	93%	0.9333
3C09_NAG_A_3371	18%	41%	0.233	0.829	0.55	1.77	-	4	3	0	93%	0.9333
3C09_NAG_D_3891	12%	68%	0.236	0.776	0.57	0.65	-	-	0	0	93%	0.9333
3C09_NAG_D_3371	7%	52%	0.271	0.741	0.5	1.36	-	2	0	0	93%	0.9333
3C09_NAG_A_4202	2%	56%	0.425	0.723	0.56	1.1	-	1	0	0	93%	0.9333
4KRM_NAG_G_605	57%	81%	0.135	0.909	0.34	0.48	-	-	0	0	100%	0.9333
3B2U_NAG_E_3371	45%	52%	0.129	0.858	0.55	1.3	-	3	0	0	100%	0.9333
6B3S_NAG_B_602	36%	58%	0.154	0.848	0.52	1.06	-	2	2	0	100%	0.9333
4KRL_NAG_A_603	21%	78%	0.231	0.837	0.28	0.6	-	-	1	0	100%	0.9333
1OC7_NAG_A_500	100%	60%	0.04	0.991	0.61	0.9	-	1	0	0	100%	0.9333
1OC6_NAG_A_500	100%	67%	0.041	0.988	0.46	0.8	-	1	0	0	100%	0.9333
1UWC_NAG_A_262	100%	54%	0.046	0.99	0.81	0.95	-	-	0	0	100%	0.9333
6ZE6_NAG_B_703	99%	52%	0.044	0.984	0.78	1.07	-	2	0	0	100%	0.8667
6ZE2_NAG_B_704	99%	56%	0.042	0.979	0.73	0.95	-	1	0	0	100%	0.9333

RCSB PDB Core Operations are funded by the National Science Foundation (DBI-1832184), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM133198.